In this study, we aimed to investigate the therapeutic efficacy in metastatic PCa of suppressing the survival and function of TIL-Bs by inhibiting BTK signaling using ibrutinib and how this affects the PCa TME to sensitize anti-PD-1 blockade. This evidence concerns the gene PDCD1 and posterior cortical atrophy.